longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

GSK

GSK

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 16.14, within the reasonable range, cheaper than 42.35% of the time in the past 3 years, and the industry ranks 27/257, the industry Median -1.30.

16.14xP/E
$51.06Stock price
$3.16Earnings per share
16.14xP/E
Stock price$51.06Earnings per share$3.16

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
15.51x
Typical range
13.35x–19.56x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
0295887116

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
P/E ratio
Name/Symbol
NVOUSNovo Nordisk AS
10.55x6.54%$191.02B
BMYUSBristol Myers Squibb
13.83x62.25%$128.36B
GSKUSGSK
16.14x6.56%$104.05B
UCBJYUSUCB S.A.
17.93x--$45.66B
HLNUSHaleon
19.00x2.92%$41.23B
OTSKYUSOtsuka Pharmaceutical
14.62x--$37.85B
ZTSUSZoetis
11.44x6.81%$30.17B
ALPMYUSAstellas Pharma
11.68x--$27.24B
JAZZUSJazz Pharma
16.83x349.11%$15.83B
OPHLYUSOno Pharmaceutical
14.76x--$7.19B
INDVUSIndivior Pharmaceuticals
11.83x126.83%$4.21B
SNPHYUSSanten Pharmaceutical
14.87x--$3.67B
OGNUSOrganon
17.20x211.11%$3.60B
HRMYUSHarmony Biosciences
13.73x45.48%$2.49B
PBHUSPrestige Brands
12.80x7.48%$2.20B
GTBIFUSGreen Thumb Industries Inc.
13.44x--$1.70B
ANIPUSANI Pharma
17.01x49.55%$1.69B
PAHCUSPhibro Animal Health
14.02x26.75%$1.40B
OMERUSOmeros
10.70x1,880.00%$1.34B
CRONUSCronos
17.74x902.68%$1.24B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.